‘We think in decades’: J&J’s $30B spending spree may not be over
After Johnson & Johnson has doled out more than $30 billion for Abiomed, Laminar and Shockwave Medical, are more medtech deals on the way?
Cardiovascular focus has led to growth
J&J’s recent medtech spending has been focused on companies with devices to treat heart conditions: Abiomed makes Impella cardiac pumps; Laminar makes devices to treat a condition in the left atrial appendage of the heart; and Shockwave’s devices treat coronary and peripheral artery disease.
The flurry of deals in this space has already helped fuel growth for the company’s cardiovascular unit, previously called interventional solutions. Overall, the segment brought in $1.81 billion in sales in the first quarter, roughly 20% growth year over year.
In 2022, before the integration of Abiomed, J&J’s interventional solutions unit had $4.3 billion in total sales, growing year over year at just over 8%.
Tim Schmid, head of J&J’s medtech businesses, told investors that Abiomed continues to “perform ahead of the deal model.” Meanwhile, his comments on the recent Shockwave deal echoed Duato’s on high growth M&A targets, and they could be a hint at factors J&J would consider for another medtech purchase.
Keep up with the story. Subscribe to the MedTech Dive free daily newsletter
“[Shockwave] will be our third very thoughtful and deliberate move to only participate in high growth, high margin cardiovascular areas, where there is significant unmet need and tremendous opportunity for us to grow,” Schmid said.
Electrophysiology was the strongest piece in the cardiovascular segment, growing at 23% year over year to $1.34 billion in the quarter. The space has recently received a lot of attention from industry and Wall Street analysts as pulsed field ablation (PFA) devices hit the market.
Boston Scientific and Medtronic received approval from the Food and Drug Administration for their respective PFA systems, and both are beginning U.S. launches.
Last month, J&J said it submitted a premarket approval application to the FDA for its Varipulse PFA system. Varipulse has received market authorization in Europe and Japan, though J&J may continue to trail Medtronic and Boston Scientific in the U.S. in the foreseeable future.
Schmid, noting that J&J cannot control the review process, said the company expects an FDA approval to come through by the end of this year or early next year.